Holen Sie sich die Stockscreener-App
3.02
0.67%
0.02
Alzamend Neuro Inc Aktie (ALZN) Neueste Nachrichten
Alzamend Neuro (ALZN) Secures $5 Million in Private Placement | - GuruFocus
Fast-Tracked: $5M Investment Accelerates 5 Phase II Trials for Alzheimer's and Mental Health Breakthroughs - Stock Titan
Alzamend Neuro (NASDAQ:ALZN) Stock Rating Upgraded by Wall Street Zen - Defense World
Alzamend Neuro Stock: A Green Day Hiding Red Flags for Traders - thekhabrilal
Citadel Advisors LLC Makes New Investment in Alzamend Neuro, Inc. (NASDAQ:ALZN) - Defense World
Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Significant Growth in Short Interest - Defense World
Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 18.6% in May - Defense World
Promising Pharmaceutical Stocks To Follow Today – May 29th - Defense World
Lithium Stocks To Consider – May 29th - Defense World
Alzamend Neuro begins phase II trial for novel lithium delivery system By Investing.com - Investing.com South Africa
Alzamend Neuro doses first patient in Phase II study of AL001 - TipRanks
Alzamend Neuro (ALZN) Begins Phase II Clinical Study of AL001 | - GuruFocus
Sector Update: Health Care - marketscreener.com
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled - Asianet Newsable
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled By Stocktwits - Investing.com India
Lithium Stocks To ConsiderMay 29th - MarketBeat
Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone - Benzinga
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results - Benzinga
Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue - Benzinga
Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update - TipRanks
Alzamend Neuro Soars on Breakthrough Trial News: Is This Biotech Stock a Hidden Gem? - RagingBull
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
Alzamend Neuro begins phase II trial for novel lithium delivery system - Investing.com Australia
Alzamend Neuro (ALZN) Begins Phase II Clinical Study of AL001 | ALZN Stock News - GuruFocus
Alzamend Neuro Announces Dosing Of First Patient In Phase II Clinical Trial Of Al001 "Lithium In Brain" Study - marketscreener.com
Alzamend Neuro Announces Dosing of First Patient in its - GlobeNewswire
Novel Lithium Drug Enters Phase II Trial, Targets 43M Patients With Brain Disorders Without Blood Monitoring - Stock Titan
Alzamend Neuro (NASDAQ:ALZN) Trading Down 5.5% – Here’s What Happened - Defense World
Alzamend begins phase II trial for novel lithium therapy By Investing.com - Investing.com South Africa
Alzamend begins phase II trial for novel lithium therapy - Investing.com Australia
Alzamend Neuro (ALZN) Commences Phase II Trial for Innovative Al - GuruFocus
Alzamend Neuro (ALZN) Commences Phase II Trial for Innovative Alzheimer's Treatment | ALZN Stock News - GuruFocus
Alzamend Neuro Enrolls First Patient in its Phase II - GlobeNewswire
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study - marketscreener.com
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - Stock Titan
Alzamend Neuro (ALZN) Begins Key Phase II Trials of AL001 | ALZN Stock News - GuruFocus
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 'Lithium in Brain” Study Taking Place at Massachusetts General Hospital - The Manila Times
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - Stock Titan
EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants - Benzinga
Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested - The Globe and Mail
Alzamend Neuro to conduct reverse stock split - MSN
Alzamend Neuro adds partners for lithium study using specialty head coil - AuntMinnie
Alzamend Neuro announces reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com India
Alzamend Neuro Announces Reverse Stock Split Plan - TipRanks
Stock Market Recap: Alzamend Neuro Inc (ALZN) Concludes at 0.60, a -6.22 Surge/Decline - DWinneX
Alzamend Neuro (ALZN) Announces Reverse Stock Split | ALZN Stock News - GuruFocus
Alzamend Neuro Announces Reverse Stock Split - The Manila Times
Alzamend Neuro announces reverse stock split to meet Nasdaq requirements - Investing.com
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital - BioSpace
Alzamend Neuro partners with Mint Labs to support five upcoming trials - TipRanks
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered - GlobeNewswire
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical ... - Eagle-Tribune
EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program - Yahoo
Geode Capital Management LLC Buys New Stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) - Defense World
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital - Seeking Alpha
ALZNAlzamend Neuro Inc Latest Stock News & Market Updates - Stock Titan
1.62%
0.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):